• Pfizer agrees to slash prescription drug prices by an average of 50% or more for Medicaid and direct-to-consumer channels
  • The deal grants Pfizer a three-year tariff grace period in exchange for maintaining U.S. manufacturing investments
  • Administration officials indicate this sets a precedent for similar negotiations with other major pharmaceutical companies

President Trump and Pfizer have reached a sweeping agreement that will see the pharmaceutical giant offer substantial discounts—averaging 50% or more—on many of its prescription drugs for Americans, according to people familiar with the negotiations. The arrangement, finalized after weeks of intense discussions, represents the administration's most significant victory in its campaign to lower U.S. drug prices.

The deal specifically targets two key areas: Medicaid programs and new direct-to-consumer channels where patients will be able to purchase medications at prices comparable to those available in other developed countries. "This is exactly what we promised American patients—fair pricing that matches what other countries pay," said a senior administration official who spoke on condition of anonymity because the details hadn't been formally announced.

In return for the price concessions, Pfizer receives protection from potential tariffs for three years, provided the company continues its current level of U.S. manufacturing investment. The grace period offers Pfizer crucial stability amid the administration's broader trade policy initiatives, according to analysts who have been briefed on the terms.

The agreement comes after President Trump sent direct letters to 17 major pharmaceutical companies last month, demanding they adopt Most-Favored-Nation pricing policies and establish direct sales channels to consumers at international price levels. Administration officials had warned of potential regulatory actions and tariffs for companies that failed to comply.

Pfizer's leadership has been under particular scrutiny given the company's position as one of the world's largest pharmaceutical manufacturers by revenue. While the company reported robust growth last fiscal year, driven partly by ongoing COVID-19 product sales, the new pricing structure will likely pressure profit margins in the short term.

Initial market reaction saw Pfizer's stock rise moderately in after-hours trading, suggesting investors view the clarity around pricing policy as preferable to continued uncertainty. "The market hates uncertainty more than it hates margin compression," noted one healthcare analyst who requested anonymity to discuss the sensitive negotiations.

The White House declined to comment on the specific terms, but officials indicated that similar discussions are underway with other major pharmaceutical manufacturers. The administration views the Pfizer agreement as establishing a template for future negotiations, according to people familiar with the matter.

Patient advocacy groups have cautiously welcomed the news, though some expressed concern about potential long-term effects on drug innovation if revenue declines industry-wide. "Immediate relief for patients is crucial, but we need to ensure this doesn't come at the cost of future medical breakthroughs," said a representative from a major healthcare consumer organization.

Correction: An earlier version of this article misstated the duration of the tariff grace period. It is three years, not two.